AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 231 min read$CTNM

RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

RBC Capital's Brian Abrahams maintained a Buy rating and $21.00 price target for Contineum Therapeutics (CTNM). The analyst has a 12.1% average return and 51.90% success rate. The Street's consensus is Strong Buy with a $22.14 average target. CTNM reported a $15.15M quarterly net loss, improving from last year's $16.04M.

Original reporting
theglobeandmail.com
Published Sep 23, 2026, 1:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 5:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$CTNMNeutralLow
01

Why it matters

Reaffirmed rating offers limited new insight; investors already aware of earnings loss.

02

Market read

Minor relevance; primarily a rating reaffirmation without fresh data.

03

What to watch

Potential pipeline developments not discussed could drive future moves.

Relevance 4/10Novelty 2/10Timing: report released yesterday

Background

RBC Capital analyst covers biotech peers; consensus remains Strong Buy with higher price targets.

Company-level read

Ticker impact

$CTNMNeutralLow confidence
Context

RBC Capital maintains Buy rating and cites latest quarterly GAAP net loss of $15.15M.

Expected impact

minimal change, likely flat to slight uptick if market values rating continuity.

Evidence & confidence

Rating unchanged; earnings already disclosed; no fresh catalyst.

Market effects

Sector

Healthcare sector sees no immediate shift from this reiteration.

Regional

U.S. market impact negligible.

Global

Limited to investors tracking Contineum.

Counterpoint

What could challenge this read

The unchanged rating may be overly cautious given the narrowing loss.

Key entities

  • Analyst Firm
    RBC Capital

    Provides coverage and rating for Contineum.

  • Company
    Contineum Therapeutics, Inc.

    Biotech firm reporting quarterly loss.

Read at source← All news

Related articles

OCT 12
$CTNMHigh

Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results

Contineum Therapeutics (CTNM) shares rose 27% premarket after Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for a pulmonary fibrosis treatment targeting the same pathway as CTNM's lead drug, PIPE-791. BMY's trial met its primary endpoint, showing improved lung function. CTNM's stock was indicated at $16.99, up from $13.38. The results may impact CTNM's valuation, though its drug remains in Phase 2.

finance.yahoo.com2 min
OCT 12
MedAI 8/10

Why is Contineum Therapeutics stock surging today?

Contineum Therapeutics stock surged 21.1% after Bristol Myers Squibb's Phase 3 trial for admilparant in pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791, an LPA1 antagonist, benefits from this validation. Analysts have Buy ratings with targets ranging from $20 to $24. The move is driven by company-specific news, not broader market trends.

investing.com2 min
OCT 12
$CTNMHighAI 8/10

Contineum Therapeutics stock surges on Bristol Myers trial win

Contineum Therapeutics (CTNM) shares rose 27% in pre-market trading after Bristol Myers Squibb's Phase 3 trial for admilparant in idiopathic pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791 targets the same biological pathway. CTNM was indicated at $16.99, up from $13.38. Stifel previously noted the trial's importance for Contineum's valuation.

uk.investing.com1 min
SEP 25
$CTNMMedAI 8/10

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

insidermonkey.com4 min